Skip to Content
Søg Menu

Overlevelsesgevinst for skrøbelige CLL-patienter i behandling med Imbruvica og Venclyxto

Hør Carsten Niemann perspektivere opdaterede data for skrøbelige patienter med CLL i kombinationsbehandling med ibrutinib og venetoclax med særlig fokus på MRD, IGHV-mutationsstatus, overlevelse samt forekomst af infektion.
Carsten Niemann

Få adgang

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Relateret indhold

Drug Sensitivity Screening to Guide Clinical Decisions for Hematologic Cancers

/ Sigrid S. Skånland
AMLCLL

ASH 2023: The Impact of Fitness and Dose Intensity on Safety and Efficacy Outcomes after Venetoclax-Obinutuzumab in Previously Untreated CLL

/ BestPractice Nordic
ASH23CLL
Jeff P. Sharman

No Increased Risk of Ventricular Arrhythmias and Sudden Death with Acalabrutinib

/ Jeff P. Sharman
ASH23CLL Play the Video 1:45
Jeff P. Sharman

Acalabrutinib in Frontline CLL Treatment: Six-Year Results from the Elevate-TN Study

/ Jeff P. Sharman
ASH23CLL Play the Video 2:45

ASH 2023: ELEVATE-TN Study – 6-Year Follow-up of Acalabrutinib Efficacy in CLL

/ BestPractice Nordic
ASH23CLL
Peter Hillmen

New Standard of Care for Previously Untreated CLL

/ Peter Hillmen
ASH23CLL Play the Video 5:40

ASH 2023: CAPTIVATE Study – Ibrutinib-Venetoclax for CLL/SLL

/ BestPractice Nordic
ASH23CLL
Paolo Ghia

CAPTIVATE Study: CLL Combination Therapy of Ibrutinib and Venetoclax

/ Paolo Ghia
ASH23CLL Play the Video 4:30
John Gribben

The Latest Advancements in the Treatment of CLL

/ John Gribben
ASH23CLL Play the Video 3:36
Back to top